Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Verrica Pharmaceuticals
VRCA
Verrica Pharmaceuticals
Restrictive Payer Policies Will Limit Dermatology Revenues But Spur Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
16 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$20.00
72.7% undervalued
intrinsic discount
16 Aug
US$5.47
Loading
1Y
-80.6%
7D
-8.3%
Author's Valuation
US$20.0
72.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$20.0
72.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-87m
227m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$227.5m
Earnings US$52.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
46.13%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$52.82m
Earnings '28
x
9.57x
PE Ratio '28
=
US$505.29m
Market Cap '28
US$505.29m
Market Cap '28
/
20.75m
No. shares '28
=
US$24.35
Share Price '28
US$24.35
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$20.00
Fair Value '25
